Clinical Trial Search

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl

Primary: Change in Percentage of HbA1c From Baseline to 3 Months — 1.6 change in percentage of HbA1c

Primary: Mean Blood Glucose Levels (Measured in mg/dL) at Randomization Are Compared to Mean Blood Glucose Levels After First Day of Treatment Among Subjects Treated With Basal…

Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin

Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants

Primary: Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles — 6.83; 7.15; 6.84 millimoles per Liter…

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c) — -1.00; -0.96; -0.98; -0.92 percentage HbA1c

Primary: Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c) — -1.12; -1.22 percentage of HbA1c — p=0.3709

Primary: Patients With Glycosylated Haemoglobin (HbA1c) Value < 7% — 22.4; 8.8 percentage of participants — p=0.0499

Primary: The Number of Participants Who Achieved a Hemoglobin A1C <7% — 5; 12 Participants

Primary: Birth Weight Per Arm — 3604; 3589 g

Primary: Percentage of Subjects Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0% — 34.4; 46.9 percentage of subjects

Primary: Change in A1c — 9.74; 7.98 percent HbA1c — p=0.004

Primary: Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose…

Primary: Change in HbA1c — -0.20; -0.53; -0.31 % of glycated haemoglobin — p=0.0039

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.27; -0.85 Percentage of HbA1c — p=<0.001

Primary: Hemoglobin A1c (HbA1c) at 36 Week Endpoint — 7.66; 7.49 percent HbA1c — p=0.097

Primary: Mean Daily BG Levels — 172; 173 mg/dL

Primary: Change From Baseline in HbA1c at 24 Weeks (Part 1) — 8.23; 8.10; 8.07; 8.38 Percentage of glycosylated hemoglobin

Primary: Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring) — 65.99; 72.86; 64.98…

Primary: Change From Baseline to Week 24 in HbA1c — -0.82; -0.42 percentage of hemoglobin — p=<0.0001

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Between Group Difference in HbA1c When Comparing CSII to MDI — -1.1; -0.4 Change in % HbA1c